Earnings Summary

Seres Therapeutics Inc’s revenue jumped +Inf% since last year same period to $3.04Mn in the Q4 2016. On a quarterly growth basis, Seres Therapeutics Inc has generated -76.67% fall in its revenue since last 3-months.

Seres Therapeutics Inc’s net profit fell -28.74% since last year same period to $-25.28Mn in the Q4 2016. On a quarterly growth basis, Seres Therapeutics Inc has generated -35.25% fall in its net profits since last 3-months.

Seres Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -832.54% in the Q4 2016. On a quarterly growth basis, Seres Therapeutics Inc has generated -479.81% fall in its net profit margins since last 3-months.

Seres Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.45 - a 4.26% jump from last quarter’s estimates.

Seres Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.45.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Seres Therapeutics Inc’s return on assets (ROA) stands at -0.44.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Seres Therapeutics Inc’s return on equity (ROE) stands at -3.52.